The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

The drug industry and hospitals have been butting heads over the future of a federal drug pricing program for more than a year, according to The Washington Post. Federal regulators may finalize ...

Hospitals are up in arms over new guidance issued by the Health Resources and Services Administration on Thursday that could restrict the eligibility of their outpatient clinics for drug discounts in ...

Hospitals and small organizations should have equal levels of oversight and scrutiny. One of the critical components for Mainers as they navigate the medical quagmire of insurance, providers and ...

In August, J&J informed disproportionate share hospitals, which care for a large number of vulnerable patients, that it would stop giving them upfront discounts on plaque psoriasis treatment Stelara ...

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...